Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer (BC) patients.

Salvatore Pece,Patrick Maisonneuve,Davide Disalvatore,Stefano Freddi,Paolo Veronesi,Marco Colleoni,Giuseppe Viale,Pier Paolo Di Fiore

Journal of Clinical Oncology（2020）

引用 0|浏览22

暂无评分

摘要

1057Background: The StemPrintER risk score (SPRS) is a 20 gene-based predictor that estimates the “degree of stemness” of the primary tumor and provides additional prognostic information regarding ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要